Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nelfinavir potency concerns

    Project Inform Perspective
    |May 29, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Recent studies indicate nelfinavir (Viracept), a common protease inhibitor, may be less effective than other HIV drugs. This overview examines findings on first-line HIV therapy options.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles

    Area of Science:

    • Virology
    • Pharmacology
    • Infectious Diseases

    Background:

    • Evaluating the efficacy of antiretroviral drugs is crucial for optimizing first-line HIV therapy.
    • Nelfinavir (Viracept) is a widely used protease inhibitor in HIV treatment regimens.

    Discussion:

    • Recent studies suggest nelfinavir may exhibit lower potency compared to other protease inhibitors.
    • Comparisons also indicate potential differences in efficacy against non-nucleoside reverse transcriptase inhibitors (NNRTIs).

    Key Insights:

    • Nelfinavir's position in first-line HIV therapy may require re-evaluation based on comparative potency data.
    • Understanding drug class efficacy is essential for personalized HIV treatment strategies.

    Outlook:

    • Further research is needed to establish optimal drug combinations for initial HIV treatment.
    • Clinical guidelines may evolve to reflect updated evidence on antiretroviral drug effectiveness.